In the current study, an effort was made to establish and evaluate a novel predictive score for NSCLC patients, with advanced disease, treated with anti-PD-1 monotherapy (nivolumab or pembrolizumab), while incorporating non-interventional, baseline, clinical parameters. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.